Bundibugyo Ebola – As health officials respond to a fast-expanding Ebola outbreak in the Democratic Republic of the Congo and Uganda, scientists warn that no licensed vaccine or treatment exists for the Bundibugyo species driving the epidemic. Emergency work is now focused on ev
On Tuesday, a World Health Organization representative in the Democratic Republic of the Congo put a blunt fact at the center of the response: for the Ebola species now spreading through the region, there is no licensed vaccine or treatment.
That matters because the outbreak is already moving faster than planners once assumed. Around 50 confirmed Ebola cases. 600 suspected cases and 130 suspected deaths are now under investigation in the Democratic Republic of the Congo and Uganda. Cases have also been detected in the major Congolese cities of Goma and Bunia. fears that the outbreak could broaden quickly.
The strain is rare and carries a long history of being overlooked in vaccine development. The epidemic is caused by the Bundibugyo species of Ebola virus. Experts say they are working on several vaccine candidates for Bundibugyo, including an mRNA vaccine—but those options are not available yet.
“This species of Ebola is one for which there is no licensed vaccine or treatment,” Anne Ancia, the World Health Organization representative in the DRC, said in a press briefing Tuesday.
Ebola has six known virus species, four of which are known to cause disease in humans. But Bundibugyo virus has caused relatively few outbreaks historically and has remained a lower research priority compared with the more lethal Zaire strain. or even Marburg virus—another member of the same viral family as Ebola. As a result, many countermeasures were built around what showed up most often.
Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security, described how that shaped today’s gap. “Most of Ebola countermeasure development has been focused on Ebola Zaire. which was traditionally the more deadly strain and has always been the more common strain behind outbreaks. ” he said. “That also means that a lot of the other Ebola strains have not necessarily had that same level of vaccine development.”.
Adalja argued that the ideal solution would go beyond chasing each outbreak’s specific culprit. “Ideally. what you’d want is kind of a universal filovirus [the family that contains Ebola and Marburg viruses] vaccine that works against all the strains of Ebola. as well as the Marburg strains. I think that would be the holy grail here.”.
Right now, the focus is on what can be evaluated quickly enough to matter. Shanelle Hall. principal adviser to the Africa Centers for Disease Control and Prevention’s director-general on management and operations. said in a press briefing that experimental vaccines and therapeutics against the Bundibugyo strain are being considered for use under randomized controlled trial protocols in the DRC and Uganda. though none have yet commenced.
Those options include the monoclonal antibody DP134 and remdesivir-based treatments. The agency is also reviewing vaccine candidates, including the live non-mRNA vaccine Ervebo, which has been used for Ebola Zaire outbreaks.
Hall said the review also includes earlier-stage Bundibugyo-focused candidates from Moderna. the University of Oxford and the International AIDS Vaccine Initiative. The inclusion of Moderna’s vaccine among the candidates under review has renewed attention on mRNA technology and whether it could help close longstanding preparedness gaps for rarer Ebola species.
Hall said the scientists are reviewing these candidates “to come up with accelerated plans and then protocols for looking at effectiveness of cross-protection between strains.”
Adalja said mRNA approaches fit the urgency. “Because of the speed with which they can be manufactured. the speed with which they can be adapted. these should be very near the top of the list when you’re thinking about vaccine development for emerging pathogens like strains of Ebola that we don’t have vaccines for.”.
A separate organization overseeing vaccine development also described how the outbreak has triggered contingency work. The Coalition for Epidemic Preparedness Innovations (CEPI). a nonprofit that funds vaccine development. said it is assessing vaccine and antibody drug candidates that could potentially be evaluated during the outbreak.
Nicole Lurie, CEPI’s executive director for preparedness and response, said in a statement: “Currently, there are no Bundibugyo-specific vaccine candidates in phase 1 [early-stage] clinical trials, but several are in preclinical development [animal studies].”
CEPI said it has activated an internal emergency response team to coordinate scientific. funding and vaccine development efforts linked to the outbreak. It is also exploring ways to rapidly advance vaccine candidates and identify manufacturers capable of producing doses for clinical trials for the current outbreak.
For public health experts, the Bundibugyo crisis is also a reminder of what readiness has failed to cover. They have called for a broader “prototype pathogen” or viral family approach to preparedness. in which countermeasures target “conserved” features shared across related viruses rather than focusing on one strain at a time.
Adalja said he has advocated for that direction for some time. “I’ve been somebody that’s advocated for a viral family approach for some time. Think about the viral family as a whole,” he said.
What’s already clear in this outbreak is that the world’s Ebola playbook is not uniform. Development has largely followed the strains that came most often. Now the response is scrambling to catch up to a species—Bundibugyo—that is rare. lower-priority. and moving through communities with no licensed vaccine or treatment built for it.
CEPI’s efforts. the Africa CDC’s planned randomized trial protocols. and renewed interest in mRNA speed all point toward a future where this kind of mismatch doesn’t cost so much time. But for people watching the confirmed cases. suspected cases. and suspected deaths climb across the DRC and Uganda—now including Goma and Bunia—the present has already become a race against the calendar.
Ebola Bundibugyo vaccine development mRNA vaccines Africa CDC World Health Organization CEPI DP134 remdesivir Ervebo randomized controlled trials filovirus preparedness